Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1599 results found

2025 ∙ Scott, J. Abers, M. S. Marwah, H. K. McCann, N. C. Meyerowitz, E. A. Richterman, A. Fleming, D. F. Holmes, E. J. Moat, L. E. Redepenning, S. G. Smith, E. A. Stoddart, C. J. Sundaram, M. E. Ulrich, A. K. Alba, C. Anderson, C. J. Arpey, M. K. Borre, E. Ladines-Lim, J. Mehr, A. J. Rich, K. Watts, C. Basta, N. E. Jarolimova, J. Walensky, R. P. Dugdale, C. M.

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026

  • All age groups
  • COVID-19
  • RSV (Respiratory syncytial virus)
  • Influenza
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Jafari, Z. Kolb, B. E. Aiken, S. Wilson, S.

Updates on Auditory Outcomes of COVID-19 and Vaccine Side Effects: An Umbrella Review

  • All age groups
  • Pregnant women
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Adusei-Mensah, F. Olubamwo, O. Olaleye, S. Akter, L. Balogun, O. S. Moshoeshoe, R. J. Awoniyi, L. Olawuni, A. Kauhanen, J.

Updating the impact of mRNA COVID-19 vaccine exposure during pregnancy on obstetric and neonatal outcomes

  • Pregnant women
  • COVID-19
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Gabor, M. Schlosserova, A. Korchynska, O. O.

Vaccination in pregnancy: a systematic review of current evidence

  • Pregnant women
  • Influenza
  • Pertussis
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Rehman, S. Sukaina, M. Aminpoor, H. Davis, S. Munir, A. B. I. Karimi, H.

Vaccine Induced Immune Thrombotic Thrombocytopenia After Sinopharm Vaccination: A Systematic Review of Case Reports

  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Low
2025 ∙ Hirsch, C. Zorger, A. M. Baumann, M. Park, Y. S. Bröckelmann, P. J. Mellinghoff, S. Monsef, I. Skoetz, N. Kreuzberger, N.

Vaccines for preventing infections in adults with solid tumours

  • Adults
  • Older adults
  • Pneumococcal disease
  • Haemophilus influenzae type B
  • Meningococcal disease
  • Pertussis
  • Hepatitis B
  • Tetanus
  • Poliomyelitis
  • Diphtheria
  • Influenza
  • Herpes zoster
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
2025 ∙ Hemrajani, P. Sharma, M. Gupta, S.

Vitiligo and coronavirus disease 2019 vaccination: A systematic review

  • All age groups
  • COVID-19
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Conseil Supérieur de la Santé (CSS)

Belgian Vaccination Strategy against COVID-19: Season 2025-2026

  • Recommendation
  • Europe
  • Belgium
  • COVID-19
Download:
2025 ∙ JCVI

JCVI statement on COVID-19 vaccination in autumn 2026 and spring 2027

  • Recommendation
  • Europe
  • United Kingdom
  • COVID-19
Download:
2025 ∙ Folkhälsomyndigheten

Recommendations for COVID-19 vaccination from September 1 2025 in Sweden

  • Recommendation
  • Europe
  • Sweden
  • COVID-19
Loading...